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Abstract
This paper introduces the background, aim and objectives of the project entitled “China—the Gates Foundation
Collaboration on TB Control in China” that has been underway for many years. It also summarizes the key findings
of the nine papers included in this special issue, which used data from the baseline survey of Phase II of the project.
Data were collected from the survey of TB and MDR-TB patients, from designated hospitals, health insurance agencies
and the routine health information systems, as well as key informant interviews and focus group discussions with
relevant key stakeholders. Key issues discussed in this series of papers include the uses of TB services and anti-TB
medicines and their determining factors related to socio-economic and health systems development; expenditures on
TB care and the financial burden incurred on TB patients; and the impact of health insurance schemes implemented in
China on financial protection.
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Multilingual abstract
Please see Additional file 1 for translations of the ab-
stract into the six official working languages of the
United Nations.
Background
In 2013, the World Health Organization (WHO) esti-
mated that China had the second highest burden of both
tuberculosis (TB) and multi-drug resistant tuberculosis
(MDR-TB) in the world [1]. According to the National
TB Epidemiology Survey conducted in 2010, the preva-
lence of pulmonary TB was 459 per 100,000. TB preva-
lence in rural areas (569 per 100,000) was almost twice
of that in urban areas. In the less developed western re-
gion, TB prevalence was 695 per 100,000, which was al-
most three times than the developed eastern region [2].
Although the high prevalence of TB is still a serious
concern in many parts of China, the 2010 Epidemiology
Survey revealed an impressive 65 % decline in smear-
positive pulmonary TB between 1990 and 2010 [2]. This
decline could be attributed to the nationwide scale-up of
the WHO-recommended DOTS strategy, which was
implemented in the public health system through the
Center for Disease Control (CDC). The implementation
of DOTS shifted TB treatment regimen from hospitals
to CDC, and significantly improved TB treatment on a
national scale.
Even with the implementation of DOTS, there is still a
lot of TB treatment in the hospital system. The poor
treatment outcome in the hospital system has been well
documented, and it is one of the main drivers of the
MDR-TB epidemic. The 2007 National TB Drug Resist-
ance Survey showed that 5.7 % of new patients and 25 %
of re-treated patients had MDR-TB [3]. Inappropriate
TB treatments and treatment interruption have been
recognized as the most important contributing factors of
high MDR-TB prevalence in China [3, 4].
According to the national government policy, essential
TB care is free of charge. However, studies have identified
additional medical costs associated with the diagnosis and
treatment of TB, such as the costs for liver-protection
drugs and extra tests, which were paid out-of-pocket by
the patients [5–7]. The diagnosis and treatment of MDR-
TB has not yet been incorporated into China’s National
TB Control and Prevention Program. MDR-TB treatment
is often expensive, with treatment duration being
24 months or longer. Expenses associated with TB and
MDR-TB treatment may be partially covered by health
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insurance for patients enrolled in one of the health insur-
ance schemes in China. However, patients still have to pay
significant amount of deductibles and co-payments. More-
over, Chinese hospitals are mostly financed by service fees,
and insurance schemes reimburse on a fee-for-services
(FFS) basis, which provide perverse incentives for hospi-
tals to offer more services, contributing to a rapid increase
in healthcare costs [8]. With the addition of considerable
non-medical costs and indirect costs associated with TB/
MDR-TB care, patients often suffer from heavy financial
burden, particularly those patients from poor households.
In the context of new round Chinese health system re-
form towards universal health coverage, the Chinese Na-
tional Health and Family Planning Commission (then the
Ministry of Health), and China Center for Disease Control
and Prevention (CDC), with the support from the Bill and
Melinda Gates Foundation, has since 2009 been develop-
ing an innovative program on TB and MDR-TB preven-
tion and control in six provinces since 2009. This paper
firstly outlines the background, aim and objectives of
Phase II of the project entitled “China—the Gates
Foundation Collaboration on TB Control in China”
(thereafter called “China–Gates TB Project”), and then
introduces the nine papers in this special issue using data
from the baseline survey of the China-Gates project.
Introduction of the China-Gates project
From 2009 to 2012, the first phase of the “China-Gates
project” focused on MDR-TB diagnosis, treatment and
financing. During the first phase of the program, China
CDC had undertaken individual pilots to improve the
diagnosis, and treatment of MDR-TB, as well as the af-
fordability of MDR-TB care. A comprehensive program
was developed that comprised of new diagnostic strat-
egies, standardized treatment based on resistance test-
ing, and collaboration between city hospitals, CDC, and
health insurance agencies [9]. The first phase has suc-
cessfully completed [9]. During the first phase, an im-
portant change in TB care and control system took
place in China, which was tasks of TB diagnosis and
treatment were shifted from CDC to the hospital system
[10]. An increasing number of county general hospitals
were appointed as TB designated hospitals. Thereafter,
the diagnosis and treatment of all TB patients were the
responsibilities of the designated hospitals. In addition,
funding for TB services will also be mainly provided by
health insurance schemes instead of the special fund ear-
marked for TB from the Ministry of Finance, as it has
been with the implementation of DOTS strategies from
the 1990s until recently [10]. Therefore, a main chal-
lenge in TB care and control that China is facing is how
TB services can be effectively financed and delivered in
the new system, for instance, how to ensure that the
county-level designated hospitals would effectively adopt
new TB diagnostic strategies and provide treatment fol-
lowing the national guidelines. The program, with these
anticipated changes in China’s national TB control pro-
gram, decided to tackle these challenges in its second
phase starting in 2012. The second phase of the project
expanded the scope of work by including all TB patients,
and integrating the financing of TB care into China’s
health insurance schemes, in line with the ongoing re-
form of public hospitals. The aim of the second phase of
the project was to establish comprehensive TB control
models which can be scaled up by the National TB Pre-
vention and Control Program in the future. Specifically,
key objectives included: (1) developing comprehensive
TB control models for effective diagnosis, treatment and
management of TB patients using innovative tools and de-
livery approaches; (2) exploring financing models and in-
centive mechanisms for TB care and control, aligning
with on-going health system reform in China; and (3)
demonstrating and verifying the effectiveness and feasibil-
ity of the comprehensive TB control models in selected
cities. A comprehensive evaluation of these interventions
is planned for late 2015. Results on the impacts of these
interventions will be disseminated afterwards.
One main component of the second phase was to de-
velop and implement new financing models of TB and
MDR-TB care and control, among others, in the three cit-
ies (Zhenjiang City, Jiangsu Province; Yichang City, Hubei
Province; and Hanzhong City, Shaanxi Province),
which are geographically located in the Eastern, Middle
and Western Region of China. The China CDC and the
three municipal governments, with the strong support
from the Gates Foundation and international experts, have
reached the agreement on the financing of TB/MDR-TB
care, in collaboration with the New Cooperative Medical
Scheme in the rural (NCMS), and Ministry of Human Re-
source and Social Security (MOHRSS) which is respon-
sible for the two urban health insurance schemes – the
urban employee basic health insurance (UEBHI) and the
urban resident basic health insurance (URBHI), as well as
the Medical Financial Assistance (MFA) schemes man-
aged by the Ministry of Civil Affairs, after several rounds
of consultations and negotiations. Two major reforms
have been put in place in the three program sites: (1) All
the health insurance schemes have agreed to increase the
reimbursement rate to 90 % for MDR-TB related inpatient
and outpatient services, and increase the reimbursement
rate to 70–80 % for TB related outpatient and inpatient
services. In addition, MDR-TB patients and TB patients
living in poverty or recognized as vulnerable based on
local policies will also receive financial subsidies for food
and transportations provided by the county Bureau of
Civil Affairs. (2) A case-based payment method would be
used to reimburse the TB designated hospitals at the pre-
fectural and county levels for their provision of TB/MDR-
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TB care, in order to motivate hospitals to provide stand-
ard treatment and contain cost. The two reforms have
since 2014 been implemented, though the implementation
plans differ slightly across project cities and counties.
A baseline survey was undertaken to understand pre-
intervention practice in TB/MDR-TB financing in the
three project cities, and implications for equity, efficiency
and effectiveness in relation to the provision, accessibility
and utilization of TB/MDR-TB related services. The aim
of the baseline survey were: (1) to better understand the
current situation of TB/MDR-TB care financing and pro-
vider payment mechanism in the three cities, and (2) to
generate baseline data to evaluate the effects of the new fi-
nancing models for TB/MDR-TB care and case-based pay-
ment methods in terms of equity and efficiency of TB
care; and (3) to examine the provision and quality of TB
care and control in different project sites. It was also
intended to generate baseline data that can be used to
compare TB/MDR-TB care before and after the above in-
terventions in each project site and evaluate their effects/
impacts at the end of the project implementation.
The baseline survey was conducted in the three project
cities (Zhenjiang, Yichang and Hanzhong) in 2013. Meth-
odological details of the baseline survey are reported in
the papers of this special issue [11–18]. Briefly, in each
city, the Gross Domestic Products (GDP) per capita in
2012 was used to classify the counties’ level of socio-
economic development into low-, middle- and high-
group. One county from each development category was
randomly selected in each city, resulting in a total of nine
counties. Data collection employed a combination of
quantitative and qualitative methods including:
1. Patient survey with TB and MDR-TB patients;
2. Key informant interviews and focus group discussions
with key stakeholders including policy-makers, service
providers, users, and health insurance managers;
3. Institution-based survey with health bureaus,
designated hospital, CDC, health insurance agencies
and civil affairs bureaus in city and county levels,
and township /community health centers using
self-administered questionnaires; Field observations
and inspections;
4. Routine data on TB suspect reporting, diagnosis,
treatment, and case management;
5. Policy document collected for review and analysis.
Researchers from four Chinese universities (the Central
China University of Science and Technology, Nanjing
Medical University, Shandong University, and Xi’an
Jiaotong University), Duke University/Duke Kunshan
University, and China CDC have participated in the data
collection and analyses, with support from the Gates
Foundation and provincial and municipal CDCs in these
project sites. This special issue is a collection of papers
presenting key findings emanating from the baseline sur-
vey. The papers were jointly produced by the researchers
from the collaborative organizations and finalized at the
two writing workshops hosted by Central China
University of Science and Technology in Wuhan and
China CDC in Beijing, respectively in 2014.
The introduction of papers
Nine papers included in this special issue aim to discuss
issues related to the utilization of TB services and anti-
TB medicines and their influencing factors of socio-
economic and health systems development, medical and
non-medical expenses of TB care and their financial bur-
dens placed on TB patients, and the impacts of health
insurance schemes implemented in China on provision
of financial protection. The last paper of this collection
tackles the increasing challenge of MDR-TB in China.
Over-provision and under-provision of TB services in the
Chinese hospitals co-exists at present. Hu and his
colleagues reported high admission rates in the project sites
of their paper, entitled “Factors that affect TB patient
admission rate and TB patient cost” and identified three
main factors that were closely associated with TB patient
admission rates: (1) economic incentives which encouraged
hospitals to generate revenues from TB services, (2) misun-
derstanding of infectious disease control that promoted
hospitalization, and (3) health insurance policies that poten-
tially induce the utilization of TB services in designated
hospitals [11]. The identification of these factors provides
evidence to develop relevant policies aimed to reduce un-
necessary inpatient services for TB patients. In the article
entitled “Anti-tuberculosis drug use in China: a retrospect-
ive study”, Huang et al. assessed inpatient medical records
from 12 sampled hospitals (three prefectural hospitals and
nine county hospitals) to judge the rational use of anti-TB
drugs based on WHO’s TB treatment guidelines [12]. The
examination of TB treatment regimens reveals that more
than half of the inpatients might be treated with irrational
regimens, and the anti-TB drugs were more appropriately
prescribed in the prefecture-level hospitals than in the
county general hospitals. In addition, the overuse of
second-line anti-TB drugs (SLD), particularly in the county
general hospitals, was a serious problem. All these reflect
that the effectiveness of TB care is in jeopardy in many
study hospitals, as inadequate regiments would result in
poor treatment outcomes, while over-provision of services
would harm the efficiency of service delivery. Hence, these
two papers highlight the importance to improve TB finan-
cing strategies such as the provider payment policies; to en-
hance professional and health education programs for TB
treatment and control at the community level; and to
strengthen clinical governance by improving the adherence
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of the hospitals to the clinical guidelines in order to achieve
acceptable effectiveness and efficiency of TB care delivery.
The over-provision of TB services often results in in-
creased expenditures, and thus likely to incur greater fi-
nancial burden on health insurance funds and the
families of the TB patients. This special issue includes
four papers examining the expenditures on TB services
and financial burden of TB care on patients. The first
paper by Jia and her colleagues examined actual prac-
tices and costs of TB services observed in the study hos-
pitals, in light of the so-called “free” essential TB care in
China [13]. The paper reported substantial medical ex-
penditures for completing TB treatment, particularly
among patients who received both outpatient and in-
patient care. The second paper by Zhou and his associ-
ates examined the incidence, intensity and determinants
of catastrophic health expenditure (CHE), using two
thresholds proposed by WHO: annual expenditure on
TB care (a) exceeds 10 % of total household income, and
(b) exceeds 40 % of the household’s non-food expend-
iture [14]. The paper revealed that the average out-of-
pocket payment for TB care exceeded both thresholds.
According to Zhou et al., some of the significant determi-
nants of CHE were age, household size, employment sta-
tus, health insurance status, and patient income as a
percentage of total household income. The paper “Are
free anti-TB drugs enough? An empirical study from three
cities in China,” written by Chen et al., shed light on the
relationship between patient treatment adherence and the
relative economic burden experienced by TB patients
[15]. The perceived economic burden of TB care erected
barriers for low-income TB patients seeking diagnosis and
treatment; however, the authors argued that non-medical
expenditures played a greater role in noncompliance than
previously thought. Li and his colleagues examined non-
medical expenditures on TB care including costs on trans-
port, accommodation and nutritional supplements, and
found 20 % of TB patients reported catastrophic expend-
iture on non-medical expenditures [16]. Economic burden
as a deterrent to pursuing medical care comes in multiple
forms. The key findings from these two papers have
brought up a serious concern on equity in financing of TB
care, and particularly its disproportionate economic
impact on the poor patients.
Two papers included in the special issue intend to assess
the impact of health insurance schemes being imple-
mented in China on financial protections for the TB pa-
tients. The first paper entitled “Disparity of TB care
reimbursement among different health insurance schemes:
Evidence from three counties in central China” by Pan and
her colleagues adopts a comprehensive approach to under-
stand China’s current medical insurance system and evalu-
ate the disparity in TB care reimbursement between the
three major insurance schemes – NCMS, UEBHI and
URBHI [17]. By comparing the three major schemes, the
authors showed that those covered under UEBHI had the
highest average reimbursement rates for TB care, while
enrollees under the NCMS had the lowest rates, again
showing that patients in lower socioeconomic classes were
more susceptible to financial hardship due to TB treatment
costs. Such a situation is worrying, as a vast majority of TB
patients living in the rural areas where only NCMS oper-
ates. While Pan et al. focused on all three health insurances
schemes in China, Xiang and colleagues focused only on
the NCMS and its effect on TB care reimbursement rates
for patients in rural China [18]. This study found significant
discrepancies between the effective and nominal reimburse-
ment rates for inpatient care, as well as inconsistencies be-
tween the rates reported in the patient database and those
reported in medical records. In addition, outpatient reim-
bursement packages were limited and less comprehensive
than inpatient packages. A key finding from their study re-
vealed that though it had some limited impact on the sever-
ity of CHE, the implementation of the NCMS did not
reduce the magnitude of CHE for TB patients. In other
words, the implementation of NCMS in rural China,
initiated a decade ago, did not provide adequate financial
protection to most TB patients.
The last paper of the special issue is “Drug-resistant tu-
berculosis control in China: progress and challenges” writ-
ten by Long and her colleagues [19]. It presents the
current situation of MDR-TB in China, and analyzes and
discusses main factors associated with such a rising
challenge the government of China is facing. The authors
also proposed strategies that China should take to tackle
MDR-TB epidemic in the years to come.
Conclusions
The survey we have undertaken has generated many in-
teresting and important findings, particularly on finan-
cing of TB/MDR-TB care and control in these program
sites. Although almost all the patients are covered by
three health insurance schemes (NCMS, UEBHI &
URBHI), at least two schemes (NCMS and URBHI) fails
to provide adequate financial protection for the use of
TB outpatient services, as they prioritized the coverage
of inpatient care in the service benefit packages. Conse-
quently, the out of pocket payment for TB and MDR-TB
outpatient services were considered high, especially for
those patients from low income groups. Catastrophic
health expenditure (CHE) in TB care seeking was not
uncommon among TB patients. In the meantime, only a
small number of TB patients enjoyed the benefits offered
by MFA schemes, as either the eligible criteria were too
strict or the procedures were too complicated. In
addition, hospital admission rates for TB patients were
high in most of hospitals we surveyed, as the service
providers might try to increase revenue through over-
Tang et al. Infectious Diseases of Poverty  (2016) 5:10 Page 4 of 5
provision of services, although the extent varied among
different cities and counties as reported in some papers
of this special issue. All these findings emanating from
the baseline survey are critical, based on which interven-
tions were proposed and are currently implemented to
improve equity, efficiency and effectiveness of TB care
and control in China.
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